Processing Magazine
  • Subscribe
  • Magazine
  • Events
  • News & Notes
  • Videos
  • Podcasts
  • Webinars
  • White Papers
  • 3D Models
  • Breakthrough Products Awards
  • Maintenance & Safety
  • Material Handling
  • Mixing & Blending
  • Powder & Bulk Processing
  • Process Control & Automation
  • Pumps, Motors & Drives
  • Valves & Actuators
  • Topics
    Maintenance & SafetyMaterial HandlingMixing, Blending & Size ReductionProcess Control & AutomationPumps, Motors & DrivesValves & ActuatorsPowder & Bulk Solids
    Resources
    MagazineEventsNews & NotesVideosPodcastsWebinarsWhite PapersBreakthrough Products Awards
    User Tools
    SubscribeAdvertiseAbout UsContact UsPrivacy PolicyTerms & Conditions
    http://www.facebook.com/ProcessingMagazine
    https://www.linkedin.com/showcase/27062974
    https://twitter.com/ProcessingMag
    1. News & Notes

    FDA’s action against Ranbaxy will cost US consumers

    June 23, 2014

    Indian drug-maker Ranbaxy Laboratories Ltd. was supposed to introduce three generic versions of branded products that could potentially save Americans millions of dollars, but problems related to regulation and manufacturing standards are delaying their launch.

    Staff
    John Moore/Getty Images North America/Thinkstock
    John Moore/Getty Images North America/Thinkstock

    Indian drug-maker Ranbaxy Laboratories Ltd. was supposed to introduce three long-awaited generic versions of blockbuster branded products that could potentially save American health-care payers millions of dollars but problems related to regulation and manufacturing standards are delaying the launch of the generic drugs for now, according to the Wall Street Journal.

    One of them, heartburn drug Nexium, is one of the biggest generators of revenue for AstraZeneca but the exclusivity of its patent expired in May. The generic version of the drug is not available yet because of manufacturing problems at Ranbaxy's facility. Another example of an expired patent that still drives significant revenues to its maker, Swiss giant Novartis AG, is blood-pressure treatment drug Diovan, the generic version of which was supposed to be launched in 2012. And last year Ranbaxy was expected to start producing a generic version of Roche Holding's treatment for eye infection in AIDS patients, called Valcyte. Both of these were delayed because of the same problems that led the U.S. Food and Drug Administration to withhold clearance for Ranbaxy's production, the Wall Street Journal reported.

    According to health insurer Excellus BlueCross BlueShield, delays to these three drugs could cost up to $125 million annually just in the 39 counties of upstate New York. Once generic versions of a branded drug are put on the market, costs can go down by up to 80 percent, the insurer said.

    Continue Reading

    Distributed control system

    Design of extension hoppers for gravimetric feeders

    Sponsored Recommendations

    Motion names new automation intelligence group vice president

    Mike Esposito will lead the Motion Automation Intelligence team, including the development and implementation of multi-year strategic business and marketing plans.

    MG America and Romaco North America announce strategic alliance in North American manufacturing equipment marketplace

    The two suppliers will combine sales, field service and support teams to offer complementary processing and packaging machinery.

    Yokogawa and FPT Software ink global partnership to advance DX solution offerings

    The partnership will help accelerate the growth of Yokogawa's DX portfolio of applications and services while helping FPT Software expand its market reach. The agreement is in...

    Efficient pressure compensation improves weighing accuracy in loss-in-weight feeders

    Electronic pressure compensation systems are more effective and reliable than traditional mechanical systems.

    Latest in News & Notes

    News & Notes

    Motion names new automation intelligence group vice president

    Motion Industries
    Nov. 29, 2023
    ID 98227990 © Markus Gann | Dreamstime.com
    News & Notes

    MG America and Romaco North America announce strategic alliance in North American manufacturing equipment marketplace

    Nov. 29, 2023

    Most Read

    Hammermill and roll crusher maintenance and operation

    dataPARC releases next-generation data historian platform

    International Powder & Bulk Solids Conference & Exhibition returns April 25-27

    Sponsored Recommendations

    Motion names new automation intelligence group vice president

    MG America and Romaco North America announce strategic alliance in North American manufacturing equipment marketplace

    Yokogawa and FPT Software ink global partnership to advance DX solution offerings

    Processing Magazine
    http://www.facebook.com/ProcessingMagazine
    https://www.linkedin.com/showcase/27062974
    https://twitter.com/ProcessingMag
    • About Us
    • Contact Us
    • Advertise
    • Do Not Sell or Share
    • Privacy Policy
    • Terms & Conditions
    © 2023 Endeavor Business Media, LLC. All rights reserved.
    Endeavor Business Media Logo